Squarepoint’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.62M | Sell |
191,900
-574,300
| -75% | -$15M | 0.01% | 1645 |
|
|
2026
Q1 | $21.5M | Sell |
766,200
-1,352,700
| -64% | -$36M | 0.03% | 671 |
|
|
2025
Q4 | $52.8M | Buy |
2,118,900
+483,200
| +30% | +$12.2M | 0.06% | 389 |
|
|
2025
Q3 | $41.7M | Buy |
1,635,700
+817,400
| +100% | +$20.2M | 0.04% | 465 |
|
|
2025
Q2 | $19.8M | Sell |
818,300
-543,200
| -40% | -$12.7M | 0.02% | 768 |
|
|
2025
Q1 | $34.5M | Buy |
1,361,500
+570,000
| +72% | +$14.9M | 0.04% | 460 |
|
|
2024
Q4 | $21M | Buy |
791,500
+168,300
| +27% | +$4.57M | 0.02% | 747 |
|
|
2024
Q3 | $18M | Sell |
623,200
-44,600
| -7% | -$1.3M | 0.03% | 638 |
|
|
2024
Q2 | $18.7M | Sell |
667,800
-1,366,000
| -67% | -$37.6M | 0.03% | 616 |
|
|
2024
Q1 | $56.4M | Buy |
2,033,800
+704,700
| +53% | +$19.6M | 0.1% | 220 |
|
|
2023
Q4 | $38.3M | Buy |
1,329,100
+71,200
| +6% | +$2.15M | 0.07% | 304 |
|
|
2023
Q3 | $41.7M | Buy |
1,257,900
+451,500
| +56% | +$16M | 0.1% | 209 |
|
|
2023
Q2 | $29.6M | Buy |
806,400
+374,700
| +87% | +$14.6M | 0.09% | 233 |
|
|
2023
Q1 | $17.6M | Sell |
431,700
-19,800
| -4% | -$855K | 0.07% | 310 |
|
|
2022
Q4 | $23.1M | Sell |
451,500
-273,600
| -38% | -$13.1M | 0.09% | 217 |
|
|
2022
Q3 | $31.7M | Buy |
725,100
+163,300
| +29% | +$7.94M | 0.16% | 125 |
|
|
2022
Q2 | $29.5M | Buy |
561,800
+136,600
| +32% | +$6.96M | 0.16% | 132 |
|
|
2022
Q1 | $22M | Buy |
425,200
+199,200
| +88% | +$10.3M | 0.09% | 214 |
|
|
2021
Q4 | $13.3M | Sell |
226,000
-27,900
| -11% | -$1.38M | 0.04% | 427 |
|
|
2021
Q3 | $10.9M | Sell |
253,900
-11,800
| -4% | -$523K | 0.03% | 470 |
|
|
2021
Q2 | $10.4M | Buy |
265,700
+226,100
| +571% | +$8.79M | 0.04% | 448 |
|
|
2021
Q1 | $1.44M | Buy |
39,600
+34,000
| +607% | +$1.21M | 0.01% | 1269 |
|
|
2020
Q4 | $206K | Sell |
5,600
-3,148
| -36% | -$115K | ﹤0.01% | 2490 |
|
|
2020
Q3 | $305K | Hold |
8,748
| – | – | ﹤0.01% | 1787 |
|
|
2020
Q2 | $271K | Buy |
+8,748
| New | +$297K | ﹤0.01% | 1666 |
|
|
2020
Q1 | – | Sell |
-12,121
| Closed | -$451K | – | 2356 |
|
|
2019
Q4 | $451K | Sell |
12,121
-6,956
| -36% | -$248K | ﹤0.01% | 1827 |
|
|
2019
Q3 | $650K | Buy |
19,077
+4,953
| +35% | +$180K | 0.01% | 1482 |
|
|
2019
Q2 | $580K | Buy |
14,124
+633
| +5% | +$25.1K | 0.01% | 1578 |
|
|
2019
Q1 | $544K | Buy |
+13,491
| New | +$540K | 0.01% | 1447 |
|
Other funds holding PFE
Squarepoint's PFE Position: Q2 2026 in Review
Squarepoint reduced its Pfizer (PFE) stake by 39% in Q2 2026, selling an estimated $55.6M and leaving 3,310,002 shares worth $79.7M. The position accounts for 0.09% of the portfolio, ranked #223.
Squarepoint first reported a position in PFE in Q1 2015 and has held it in 42 quarters since. The position peaked at $262M in Q3 2025. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Squarepoint held 3,310,002 shares of Pfizer worth $79.7M as of Q2 2026.
- Squarepoint sold 2,123,649 Pfizer shares in Q2 2026, an estimated $55.6M.
- Pfizer made up 0.09% of Squarepoint's portfolio in Q2 2026, its #223 holding.
- Squarepoint first reported a position in Pfizer in Q1 2015 and has held it in 42 quarters since.
- Squarepoint's Pfizer position peaked at $262M in Q3 2025.
- 2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.